• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.

作者信息

Demarzo Maria Giulia, Bodini Giorgia, Vanello Mattia, Martini Martina, Giannini Edoardo G

机构信息

Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

出版信息

Aliment Pharmacol Ther. 2021 May;53(9):1044-1045. doi: 10.1111/apt.16301.

DOI:10.1111/apt.16301
PMID:33831237
Abstract
摘要

相似文献

1
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.信函：对于炎症性肠病初次使用生物制剂失败的患者，维多珠单抗或第二种抗肿瘤坏死因子药物——疗效无差异
Aliment Pharmacol Ther. 2021 May;53(9):1044-1045. doi: 10.1111/apt.16301.
2
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.信函：维多珠单抗或第二种抗 TNF 药物——对炎症性肠病原发性生物制剂失效患者的疗效无差异。作者回复。
Aliment Pharmacol Ther. 2021 May;53(9):1046-1047. doi: 10.1111/apt.16352.
3
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.比较抗 TNF 药物与维得利珠单抗作为炎症性肠病二线生物治疗药物的药物生存：来自全国瑞典登记处的结果。
Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. doi: 10.1111/apt.16193. Epub 2020 Dec 19.
4
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
Aliment Pharmacol Ther. 2021 Mar;53(5):640-641. doi: 10.1111/apt.16212.
5
Biologic drugs for inflammatory bowel disease.用于炎症性肠病的生物药物。
Nihon Rinsho. 2017 Mar;75(3):403-407.
6
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.社论：抗TNF药物与维多珠单抗作为二线治疗药物的比较？平局并不意外——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):642-643. doi: 10.1111/apt.16241.
7
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.接受维得利珠单抗、抗 TNF 或常规治疗的炎症性肠病患者的妊娠结局：欧洲 CONCEIVE 研究结果。
Aliment Pharmacol Ther. 2020 Jan;51(1):129-138. doi: 10.1111/apt.15539. Epub 2019 Nov 6.
8
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.炎症性肠病患者对生物治疗（抗 TNF、Vedolizumab 和 Ustekinumab）的主要反应的预测因素：从基础科学到临床实践。
J Crohns Colitis. 2020 Jun 19;14(5):694-709. doi: 10.1093/ecco-jcc/jjz195.
9
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.炎症性肠病患者生物制剂的恰当治疗药物监测。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.
10
Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.维多珠单抗治疗与改善炎症性肠病患者的睡眠质量和情绪有关。
Dig Dis Sci. 2017 Jan;62(1):197-206. doi: 10.1007/s10620-016-4356-2. Epub 2016 Oct 28.